Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients

Lung Cancer

Volumn 53, Issue 1, 2006, Pages 103-109

  Scartozzi, Mario ^a   Franciosi, Vittorio ^b   Campanini, Nicoletta ^c   Benedetti, Giovanni ^d   Barbieri, Fausto ^e   Rossi, Giulio ^f   Berardi, Rossana ^a   Camisa, Roberta ^b   Silva, Rosa Rita ^g   Santinelli, Alfredo ^h   Ardizzoni, Andrea ^b   Crinò, Lucio ^d   Rindi, Guido ^c   Cascinu, Stefano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d BELLARIA HOSPITAL   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g Ospedale Profili   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Lung cancer; Mismatch repair system; Predictive factors

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE PAIR MISMATCH; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33744790898     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.03.008     Document Type: Article

References (21)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al., Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med 346 (2002) 92-98
2. Auersperg N., Edelson M.I., Mok S.C., Johnson S.W., and Hamilton T.C. The biology of ovarian cancer. Semin Oncol 25 (1998) 281-304
3. Monzo M., Rosell R., and Taron M. Drug resistance in non-small cell lung cancer. Lung Cancer 34 (2001) S91-S94
4. Colella G., Marchini S., D'Incalci M., Brown R., and Broggini M. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer 80 (1999) 338-343
5. Rosell R., Lord R.V., Taron M., and Reguart N. DNA repair and cisplatin resistance in non small cell lung cancer. Lung Cancer 38 (2002) 217-227
6. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56 (1996) 3087-3090
7. Fink D., Nebel S., Norris P.S., Aebi S., Kim H.K., Haas M., et al. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells. Br J Cancer 77 (1998) 703-708
8. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., and Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the MLH1 gene promoter. Cancer Res 60 (2000) 6039-6044
9. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., et al. The role of MLH1, hMSH3 and MSH2 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58 (1998) 3579-3585
10. Samimi G., Fink D., Varki N.M., Husain A., Hoskins W.J., Alberts D.S., et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6 (2000) 1415-1421
11. Mackay H.J., Cameron D., Rahilly M., Mackean M.J., Paul J., Kaye S.B., et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 18 (2000) 87-93
12. Paulson T.G., Wright F.A., Parker B.A., Russack V., and Wahl G.M. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 56 (1996) 4021-4026
13. Scartozzi M., De Nictolis M., Galizia E., Carassai P., Bianchi F., Berardi R., et al. Loss of MLH1 Expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur J Cancer 39 (2003) 1144-1149
14. Gryfe R., Kim H., Hsieh E.T.K., Aronson M.D., Holowaty E.J., Bull S.B., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2000) 69-77
15. Wang Y.C., Lu Y.P., Tseng R.C., Lin R.K., Chang J.W., Chen J.T., et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 111 (2003) 887-895
16. Hsu H.S., Wen C.K., Tang Y.A., Lin R.K., Li W.Y., Hsu W.H., et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 11 (2005) 5410-5416
17. Chiaravalli A.M., Furlan D., Facco C., Tibiletti M.G., Dionigi A., Casati B., et al. Immunohistochemical pattern of MSH2/MLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 438 (2001) 39-48
18. Chang J.W., Chen Y.C., Chen C.Y., Chen J.T., Chen S.K., and Wang Y.C. Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. Clin Cancer Res 6 (2000) 1639-1646
19. Cawkwell L., Gray S., Murgatroyd H., Sutherland F., Haine L., Longfellow M., et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 45 (1999) 409-415
20. Saphir A. Pathology vs. prognosis: are hereditary cancers a different breed?. J Natl Cancer Inst 90 (1998) 880-882
21. Belijanski V., Marzilli L.G., and Doetsch P.W. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol Pharmacol 65 (2004) 1496-1506